Anti-β2-glycoprotein I/HLA-DR Antibody and Adverse Obstetric Outcomes.
HLA class II
antiphospholipid syndrome
autoantibody
fetal growth restriction
hypertensive disorders of pregnancy
preterm delivery
recurrent pregnancy loss
β2-glycoprotein I
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
30 Jun 2023
30 Jun 2023
Historique:
received:
10
06
2023
revised:
28
06
2023
accepted:
29
06
2023
medline:
17
7
2023
pubmed:
14
7
2023
entrez:
14
7
2023
Statut:
epublish
Résumé
Anti-β2-glycoprotein I/HLA-DR (anti-β2GPI/HLA-DR) antibody has been reported to be associated with antiphospholipid syndrome and recurrent pregnancy loss (RPL). We conducted a prospective multicenter cross-sectional study aimed at evaluating whether the anti-β2GPI/HLA-DR antibody is associated with adverse obstetric outcomes and RPL. From 2019 to 2021, serum anti-β2GPI/HLA-DR antibody levels (normal, <73.3 U) were measured in 462 women with RPL, 124 with fetal growth restriction (FGR), 138 with hypertensive disorders of pregnancy (HDP), 71 with preterm delivery before 34 gestational weeks (preterm delivery (PD) ≤ 34 GWs), and 488 control women who experienced normal delivery, by flow cytometry analysis. The adjusted odds ratios (aORs) of anti-β2GPI/HLA-DR antibody positivity for adverse obstetric outcomes and RPL were evaluated on the basis of comparisons between the control and each patient group, using multivariable logistic regression analysis. The following were the positivity rates for the anti-β2GPI/HLA-DR antibody in the patient and control groups: RPL, 16.9%; FGR, 15.3%; HDP, 17.4%; PD ≤ 34 GWs, 11.3%; and the control, 5.5%. It was demonstrated that anti-β2GPI/HLA-DR antibody positivity was a significant risk factor for RPL (aOR, 3.3 [95% confidence interval {CI} 1.9-5.6],
Identifiants
pubmed: 37446134
pii: ijms241310958
doi: 10.3390/ijms241310958
pmc: PMC10342169
pii:
doi:
Substances chimiques
HLA-DR Antigens
0
Autoantibodies
0
beta 2-Glycoprotein I
0
Types de publication
Multicenter Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Japan Agency for Medical Research and Development
ID : JP21gk0110047, JP21fk0108137, and JP22gk0110061
Organisme : Japan Society for the Promotion of Science
ID : Kakenhi Grant-in-Aid 20K09642, 23K0888
Références
N Engl J Med. 2002 Jan 24;346(4):282-4
pubmed: 11807155
Proc Natl Acad Sci U S A. 1990 Jun;87(11):4120-4
pubmed: 2349221
BJOG. 2003 Apr;110 Suppl 20:71-5
pubmed: 12763116
J Exp Med. 1994 Feb 1;179(2):457-62
pubmed: 7507506
Obstet Gynecol. 2019 Jan;133(1):1
pubmed: 30575675
Arthritis Rheumatol. 2022 Jan;74(1):105-111
pubmed: 34164946
Fertil Steril. 2020 Mar;113(3):533-535
pubmed: 32115183
Blood. 2015 Apr 30;125(18):2835-44
pubmed: 25733579
Br J Dermatol. 2018 Jan;178(1):272-275
pubmed: 28403571
Arthritis Rheum. 1994 Oct;37(10):1453-61
pubmed: 7945470
Blood. 2010 Aug 26;116(8):1336-43
pubmed: 20462962
Arthritis Rheumatol. 2017 Oct;69(10):2069-2080
pubmed: 28575531
Physiology (Bethesda). 2009 Jun;24:147-58
pubmed: 19509125
Obstet Gynecol. 2018 Jul;132(1):e44-e52
pubmed: 29939940
Sci Adv. 2022 Mar 4;8(9):eabj9867
pubmed: 35245125
EMBO J. 1999 Nov 15;18(22):6228-39
pubmed: 10562535
J Reprod Immunol. 2023 May 18;158:103955
pubmed: 37253286
Hum Reprod Open. 2023 Mar 02;2023(1):hoad002
pubmed: 36873081
Nat Methods. 2006 Dec;3(12):995-1000
pubmed: 17072308
J Thromb Haemost. 2006 Feb;4(2):295-306
pubmed: 16420554
Hypertension. 2020 Apr;75(4):918-926
pubmed: 32063058
Haematologica. 1993 Jan-Feb;78(1):1-4
pubmed: 8491417
Proc Natl Acad Sci U S A. 2014 Mar 11;111(10):3787-92
pubmed: 24567378
Arthritis Rheumatol. 2020 Nov;72(11):1882-1891
pubmed: 32583563
Int Immunol. 2013 Apr;25(4):235-46
pubmed: 23334921